A Phase 3 Evaluation of Daclatasvir and Sofosbuvir With Ribavirin in Cirrhotic Subjects With Genotype 3 Chronic Hepatitis C Infection
Description
Phase
Phase 3 - a treatment has shown activity against a particular disease, where it is either added to existing treatment or compared to the standard treatment.Inclusion and Exclusion Criteria
- Genotype 3 HCV
- HCV RNA ≥10000 IU (International Unit)/mL
- Compensated Liver Cirrhosis
- BMI 18-40 kg/m2
- Previously treated for HCV or never treated for HCV
- Mixed infection of any genotype - Evidence of decompensated liver disease - Previous exposure to NS5A inhibitors Other protocol defined inclusion/exclusion criteria could apply
Sites
Please contact the trial administrator to learn more about where you can participate in this trial. Please use the contact form on the right side.